GlassScriptPhysician profile
Hina Aamir
NPI 1376777979
$4,943.35
in general payments reported to CMS, 2019-2025
21 companies · $911 in 2025
The $911 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $160 · 2021: $376 · 2022: $311 · 2023: $823 · 2024: $2,091 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,823 · Travel and Lodging: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,823.39 |
| Travel and Lodging | $1,001.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,587.36 | 2024-2025 | Neurostar Tms Therapy System |
| Abbvie INC. | $563.55 | 2022-2025 | Vraylar |
| Alkermes, INC. | $365.75 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $331.44 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $290.11 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $288.05 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $276.19 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $241.49 | 2019-2022 | |
| Corium, LLC | $185.63 | 2022-2024 | Azstarys |
| Lundbeck LLC | $176.28 | 2019-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $104.74 | 2021-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $90.91 | 2024-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $89.43 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $85.01 | 2025 | Cobenfy |
| Allergan, INC. | $64.84 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $48.14 | 2019 | |
| Supernus Pharmaceuticals, INC. | $37.88 | 2021-2022 | |
| Tris Pharma INC | $36.32 | 2024-2025 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $31.88 | 2021 | |
| Collegium Pharmaceutical, INC. | $24.74 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $23.61 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hina Aamir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.